Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.13
−$0.0038 · -2.84%
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Latest quote
$0.13
−$0.0038 · -2.84%
After-hours
$0.133
+$0.003 · +2.31%
Oct 8, 7:28 PM ET
Regular session · ET · Market data may be delayed.
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Day range
Current $0.13
52-week range
Current $0.13
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
21
Expensive
Sentiment
53
Mixed
Risk
66
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Day range
Current $0.13
52-week range
Current $0.13
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 269K USD | 300K USD | 189K USD | 270K USD |
| Cost of goods sold | 684K USD | 1.94M USD | 1.31M USD | 875K USD | 1.16M USD |
| Gross profit | −684K USD | −1.67M USD | −1.01M USD | −686K USD | −888K USD |
| Research and development | 10.64M USD | 4.63M USD | 15.4M USD | 17.86M USD | 15.36M USD |
| Selling, general, and administrative | 10.57M USD | 6.98M USD | 11.54M USD | 5.37M USD | 4.4M USD |
| Operating expenses | 21.21M USD | 60.81M USD | 26.94M USD | 23.23M USD | 19.76M USD |
| Interest income | 477K USD | 423K USD | 3K USD | 39K USD | 3K USD |
| Interest expense | 2.91M USD | −1.1M USD | 1.66M USD | 137K USD | — |
| Depreciation and amortization | 970K USD | 1.39M USD | 532K USD | 495K USD | 336K USD |
| Operating income | −21.89M USD | −62.48M USD | −27.94M USD | −23.91M USD | −20.65M USD |
| Net income | −25.08M USD | −53.76M USD | −38.15M USD | −23.67M USD | −19.94M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
